Frequency Therapeutics (Woburn, Mass.) recently announced data related to its experimental FX-322 drug.
The small Phase 1/2 study, published in Otology & Neurotology, found hearing improvements in adults with age-related sensorineural hearing loss.
At present, there are no FDA-approved drugs for preventing or restoring such hearing loss. However, administering steroids can facilitate recovery of hearing for some patients with sudden sensorineural hearing loss.
The Frequency Therapeutics study found that participants who received a single dose FX-322 had a statistically significant increase in word recognition.
Get the full story from our sister site, Drug Discovery & Development.